PMC:7105881 / 51255-51464
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1603 | 64-72 | Species | denotes | MERS-CoV | Tax:1335626 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T293 | 32-39 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T9112 | 32-39 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T279 | 0-209 | Sentence | denotes | The above studies indicate that protein lengths to be chosen as MERS-CoV subunit vaccines and/or structure-based vaccine design can impact on the immunogenicity and/or protection of RBD-based subunit vaccines. |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T819 | 64-72 | SP_9 | denotes | MERS-CoV |
| T820 | 113-127 | BV_26 | denotes | vaccine design |
| T821 | 146-160 | BV_15 | denotes | immunogenicity |
| T80013 | 64-72 | SP_9 | denotes | MERS-CoV |
| T87612 | 113-127 | BV_26 | denotes | vaccine design |
| T81328 | 146-160 | BV_15 | denotes | immunogenicity |